Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioDiscovery and N-of-One, a provider of molecular interpretation and therapeutic strategies for precision medicine in oncology, have entered into a partnership to jointly provide integrated genomic analysis interpretation solutions.
Subscribe to our email newsletter
The deal will combine integrated components to allow clinicians to use genomic data generated by laboratories more easily and efficiently to discover targeted therapeutic options suitable for each specific patient as well as better understand the molecular profile of the patient’s tumor.
Both the companies have not disclosed financial terms of the agreement.
Under the deal, the two parties will jointly market and sell N-of-One’s interpretation solutions and content together with BioDiscovery’s genomic analysis software, providing laboratories and oncologists with an integrated platform from genomic data analysis through to therapeutic decision support.
BioDiscovery CEO Soheil Shams said the number of genomic variants identified as prognostic indicators, or available as possible therapeutic targets, continues to increase at a very fast rate.
"BioDiscovery’s solutions excel at helping cytogenetic and molecular laboratories quickly identify likely actionable variants from the thousands present in typical cancer cases, with a particular emphasis on copy number variants (CNVs) that drive a large number of tumor types but remain difficult to interpret," Shams said.
"N-of-One completes the solution by taking this narrowed list and elucidating the possible therapeutic options based on an understanding of these variants in the context of the disease biology."
N-of-One CEO Chris Cournoyer said that the company is committed to its mission of enabling precision medicine for clinicians and researchers by providing outstanding molecular interpretation.
"Working with BioDiscovery, developer of genomics visualization and analysis software that is already in use at many cancer centers, hospitals, and independent laboratories, we are able to strengthen the point-of-care by adding a wealth of disease-specific knowledge from the latest research findings and drug trials," Cournoyer said.
"This gives oncologists and treating clinicians additional insights into possible therapeutic strategies that are informed by the patient’s disease, genomic profile, available therapies and trials, and current research."